An intra articular injectable Mitocelle recovers dysfunctional mitochondria in cellular organelle disorders

Area of Science:

• Biomedical Engineering
• Mitochondrial Biology
• Osteoarthritis Research

Background:

• Mitochondrial dysfunction elevates reactive oxygen species (ROS) production, contributing to degenerative diseases.
• The NOX4-p22phox axis is a key source of ROS, and its dysregulation impairs mitochondrial function.
• A lack of effective competitive inhibitors for the NOX4-p22phox interaction exists.

Purpose of the Study:

• To develop and characterize a novel nanozyme, Mitocelle, targeting the NOX4-p22phox axis.
• To evaluate Mitocelle's therapeutic potential in an osteoarthritis (OA) mouse model.

Main Methods:

• Fabrication of a povidone micelle-based Prussian blue nanozyme (Mitocelle).
• Characterization of Mitocelle's physical properties (shape, size) and biocompatibility.
• Assessment of Mitocelle's inhibitory effect on the NOX4-p22phox interaction in chondrocytes.
• In vivo evaluation of Mitocelle's stability, cartilage uptake, and efficacy in an OA mouse model.

Main Results:

• Mitocelle, an 88 nm spherical nanozyme, is composed of biocompatible materials.
• Mitocelle competitively inhibits the NOX4-p22phox interaction, protecting chondrocytes from mitochondrial damage.
• Intra-articular injection of Mitocelle in OA mice demonstrated long-term stability, cartilage matrix uptake, and reduced joint degradation.

Conclusions:

• Mitocelle effectively targets the NOX4-p22phox axis as a competitive inhibitor.
• Mitocelle demonstrates therapeutic potential for osteoarthritis by mitigating mitochondrial dysfunction.
• Mitocelle shows promise for translational research in OA and other mitochondrial-related degenerative diseases.